| Transcend Therapeutics, Inc. | |||
| Ticker: | TSND | 640 Memorial Drive | |
| Exchange: | NASDAQ-National Market | Cambridge, MA 02139 | |
| Industry: | Manufacturing (SIC Code 2836) | (617) 374-1200 | |
| Type of Shares: | Common Shares | Filing Date: | 3/5/97 | |
| U.S. Shares: | 1,800,000 | Offer Date: | 7/2/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.00 - $12.00 | |
| Primary Shares: | 1,800,000 | Offer Price: | $10.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.70 | |
| Offering Amount: | $19,800,000 | Selling: | $0.42 | |
| Expenses: | $824,000 | Reallowance: | $0.10 | |
| Shares Out After: | 6,136,481 |
| Manager | Tier | Phone |
| Everen Securities, Inc. | Lead Manager | (312) 574-6859 |
| Issuer's Law Firm: | Hale and Dorr |
| Bank's Law Firm: | Skadden, Arps, Slate, Meagher & Flom |
| Auditor: | Ernst & Young |
| Registrar/Transfer Agent: | Chemical Mellon Shareholder Services |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $0.00 | Assets: | $1.56 | ||
| Net Income: | -$9.21 | Curr Assets: | |||
| EPS: | -$2.35 | Liabilities: | $0.62 | ||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$3.43 | Equity: | $0.94 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is developing novel pharmaceuticals for treatment of diseases caused by oxidative stress and resultant tissue damage, with a particular therapeutic focus on critical care. The company's lead product candidate, Procysteine, has been evaluated in two Phase II clinical trials involving patients with acute respiratory distress syndrome (ARDS). In the first quarter of 1997, the company plans to begin a pivotal Phase III clinical trial of Procysteine to determine its safety and efficacy in the treatment of ARDS. Transcend is also conducting pilot clinical trials with Procysteine to determine its potential application for the treatment of amyotrophic lateral sclerosis and atherosclerotic cardiovascular disease. The company's initial product candidates are small molecule, glutathione-repleting agents designed to prevent or limit oxidative damage from reactive oxygen species, highly reactive toxic molecules produced as part of the body's immune response. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund clinical trials, research and development, redeem all outstanding shares of Nonconvertible Redeemable Preferred Stock, to acquire and/or license technology rights, products or businesses and for other general corporate purposes. |